View in Browser

Daily Briefing

Israel says it has re-established control over the Gaza border, the IMF says the global economy is 'limping along,' and Down syndrome families fight for access to Alzheimer's trials and treatments.

By Kate Turton

Today's Top News

The Israeli military imposed a blockade on the Gaza Strip. REUTERS/Mohammed Salem

ISRAEL - HAMAS WAR

Israel said it had re-established control over the Gaza border and was planting mines where Hamas militants had toppled the barrier during their bloody weekend assault, after another night of relentless Israeli air raids on the enclave. Here's the latest from the Israel-Hamas war.
Listen to Senior Correspondent Dan Williams in Jerusalem on the hostage issue complicating Israel's plans for a counter offensive.
The United Nations humanitarian office said that nearly 200,000 people, or nearly a tenth of the population, have fled their homes in Gaza since the start of hostilities and it is poised for shortages of water and electricity due to Israel's blockade.

IN OTHER NEWS

Labour leader Keir Starmer will appeal directly to British voters, saying his revamped opposition party is best placed to boost economic growth and offer the country the hope that "things will be better for your children". Here's how Starmer has plotted a painstaking path to power.
Ukrainian forces are making some headway in both the eastern and southern theatres of their four-month-old counteroffensive, military officials said. Russian accounts of the fighting said Moscow's forces had repelled Ukrainian attacks.
An artillery strike that hit a refugee camp near Myanmar's border with China has killed at least 29 people, including women and children, media and sources said, in one of the deadliest attacks on civilians since the return of military rule.
China's National Bureau of Statistics will conduct a nationwide sample survey in November to help better plan population policies, in an unexpected poll as authorities struggle to boost the country's flagging birth rate.
President Biden was interviewed as part of an investigation into his handling of classified documents by Special Counsel Robert Hur, the White House counsel's office said on Monday.

Business & Markets

The International Monetary Fund cut its growth forecasts for China and the euro area and said overall global growth remained low and uneven despite what it called the "remarkable strength" of the US economy.
Country Garden warned about its inability to meet offshore debt obligations, potentially joining a growing list of Chinese developers that have defaulted and setting the stage for one of the country's biggest debt restructurings.
Israel's shekel hit its weakest level since early 2016 and the cost of insuring the country's sovereign debt against default soared.
The US Securities and Exchange Commission has taken Elon Musk to court again, and this time it may win. The agency asked a federal court to force Musk to testify for its investigation into his $44 billion takeover of social media giant Twitter.
The global coal industry may have to shed nearly 1 million jobs by 2050, even without any further pledges to phase out fossil fuels, with China and India facing the biggest losses, research showed.
Amazon, Walmart, Target and other large retailers launched US sales, dangling discounts on narrow selections of merchandise more than six weeks before Black Friday, one of the biggest shopping days of the year.

Mapping the conflict in Israel and Gaza

The Reuters Graphics team maps the assault on Israel that began on Saturday, and how Israel's response unfolded.

Hamas gunmen kill hundreds of Israelis after breaching security barriers under the cover of thousands of rockets fired from Gaza. Israel's retaliation has included air strikes that have killed more than 400 people.

View our maps here

Down syndrome families' fight for access to Alzheimer's trials and treatments

Nine-year-old Oskar Hillerstrom with his mother Lianor and his father Hampus. REUTERS/Brian Snyder

Alzheimer's disease is the most common cause of death for people with Down syndrome.

Activists are campaigning to get them promising new drugs like Eisai and Biogen's recently approved Leqembi and Eli Lilly's experimental donanemab, as well as for inclusion of people with Down syndrome in clinical trials of treatments for Alzheimer's.

Reuters interviewed five top neurologists who recommend against immediate use because the drugs are untested in this population, whose unique predisposition to Alzheimer's could pose extra safety risks. This puts advocacy groups in the unusual position of being at odds with prominent experts in the field.

Read our insight about the families fighting for access to trials and drugs

Sponsors are not involved in the creation of newsletters or other Reuters news content.

Reuters Daily Briefing is sent 5 days a week. Think your friend or colleague should know about us? Forward this newsletter to them. They can also sign up here.

Want to stop receiving this email? Unsubscribe here.
To manage which newsletters you're signed up for, click here.